A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model.
Razonable RR, Aloia NCE, Anderson RJ, Anil G, Arndt LL, Arndt RF, Ausman SE, Bell SJ, Bierle DM, Billings ML, Bishop RK, Cramer CH, Culbertson TL, Dababneh AS, Derr AN, Epps K, Flaker SM, Ganesh R, Gilmer MA, Urena EG, Gulden CR, Haack TL, Hanson SN, Herzog JR, Heyliger A, Hokanson LD, Hopkins LH, Horecki RJ, Krishna BH, Huskins WC, Jackson TA, Johnson RR, Jorgenson B, Kudrna C, Kennedy BD, Klingsporn MK, Kottke B, Larsen JJ, Lessard SR, Lutwick LI, Malone EJ 3rd, Matoush JA, Micallef IN, Moehnke DE, Mohamed M, Ness CN, Olson SM, Orenstein R, Palraj R, Patel J, Paulson DJ, Phelan D, Peinovich MT, Ramsey WL, Rau-Kane TJ, Reid KI, Reinschmidt KJ, Seville MT, Skold EC, Smith JM, Speicher LL, Spielman LA, Springer DJ, Sweeten PW, Tempelis JM, Tulledge-Scheitel S, Vergidis P, Whipple DC, Wilker CG, Destro Borgen MJ.
Razonable RR, et al. Among authors: bishop rk.
Mayo Clin Proc. 2021 May;96(5):1250-1261. doi: 10.1016/j.mayocp.2021.03.010. Epub 2021 Mar 9.
Mayo Clin Proc. 2021.
PMID: 33958056
Free PMC article.